Pubblicazioni

Autori:

Visentin, Andrea; Mauro, Francesca Romana; Scarfò, Lydia; Gentile, Massimo; Farina, Lucia; Reda, Gianluigi; Ferrarini, Isacco; Proietti, Giulia; Derenzini, Enrico; Cibien, Francesca; Vitale, Candida; Sanna, Alessandro; Pietrasanta, Daniela; Marchetti, Monia; Murru, Roberta; Rigolin, Gian Matteo; Sportoletti, Paolo; Trimarco, Valentina; Cavarretta, Chiara Adele; Angotzi, Francesco; Cellini, Alessandro; Ruocco, Valeria; Zatta, Ivan; Laurenti, Luca; Molica, Stefano; Coscia, Marta; Ghia, Paolo; Foà, Robin; Cuneo, Antonio; Trentin, Livio

Titolo:

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Anno:

2023

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

American Journal of Hematology

ISSN Rivista:

0361-8609

N° Volume:

98

Numero o Fascicolo:

9

Intervallo pagine:

237-240

Parole chiave:

venetoclax, chronic lymphocytic leukemia, TP53

Breve descrizione dei contenuti:

Deletion of 17p13 (17p-) and/or TP53 gene mutation (TP53m), collectively defined as TP53 abnormalities (TP53 abn), can be found in 8 to 10% of treatment-naive (TN) patients with chronic lymphocytic leukemia (CLL) and in up to 50% of relapsed/refractory cases.1 In CLL TP53 disruption is a negative prognostic and predictive biomarker, associated with shorter time to first treatment, karyotype complexity, Richter transformation as well as shorter survival.2, 3 In addition, this adverse genetic feature has been associated with an increased risk of treatment failure in patients treated with continuous BTK inhibitors (BTKi).4, 5 Fixed duration venetoclax-based therapy, in combination with anti-CD20 monoclonal antibody, is a highly active treatment for TN and relapsed/refractory patients with CLL.6, 7 However, patients with TP53 abnormalities display shorter measurable residual disease (MRD) doubling time and early relapse after the end of treatment.6, 7 Continuous treatment with BTKi is a valid option in TP53 disrupted patients, counteracted by a relatively high rate of discontinuation due to adverse events,8, 9 beside second-generation BTK are better tolerated than ibrutinib. In the phase II study investigating venetoclax in TP53-disrupted patients with CLL, only five patients were TN, and 4/5 were remission-free after a median follow-up of 2 years.10 The aim of this study is to describe the efficacy and discontinuation rate of continuous venetoclax in TN CLL patients with TP53 disruption.

Id prodotto:

141586

Handle IRIS:

11562/1141706

ultima modifica:

25 ottobre 2024

Citazione bibliografica:

Visentin, Andrea; Mauro, Francesca Romana; Scarfò, Lydia; Gentile, Massimo; Farina, Lucia; Reda, Gianluigi; Ferrarini, Isacco; Proietti, Giulia; Derenzini, Enrico; Cibien, Francesca; Vitale, Candida; Sanna, Alessandro; Pietrasanta, Daniela; Marchetti, Monia; Murru, Roberta; Rigolin, Gian Matteo; Sportoletti, Paolo; Trimarco, Valentina; Cavarretta, Chiara Adele; Angotzi, Francesco; Cellini, Alessandro; Ruocco, Valeria; Zatta, Ivan; Laurenti, Luca; Molica, Stefano; Coscia, Marta; Ghia, Paolo; Foà, Robin; Cuneo, Antonio; Trentin, Livio, Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study «American Journal of Hematology» , vol. 98 , n. 9 , 2023 , pp. 237-240

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo